Zacks Investment Research cut shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a report published on Wednesday morning.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
Several other equities analysts have also commented on ASMB. BidaskClub lowered shares of Assembly Biosciences from a strong-buy rating to a buy rating in a research report on Wednesday, December 6th. ValuEngine downgraded shares of Assembly Biosciences from a hold rating to a sell rating in a report on Thursday, December 7th. B. Riley started coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a neutral rating and a $35.00 price target for the company. Finally, Jefferies Group upped their price target on shares of Assembly Biosciences to $75.00 and gave the company a buy rating in a report on Thursday, March 8th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Assembly Biosciences currently has an average rating of Buy and a consensus price target of $54.25.
Assembly Biosciences (NASDAQ ASMB) traded down $0.21 during trading on Wednesday, hitting $63.95. 18,734 shares of the stock traded hands, compared to its average volume of 160,453. Assembly Biosciences has a fifty-two week low of $18.60 and a fifty-two week high of $67.36.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $46.86, for a total value of $46,860.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 3,000 shares of company stock valued at $148,270 over the last three months. 19.60% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. MetLife Investment Advisors LLC purchased a new stake in Assembly Biosciences during the fourth quarter valued at about $326,000. Endurant Capital Management LP purchased a new stake in Assembly Biosciences during the fourth quarter valued at about $430,000. Millennium Management LLC lifted its stake in Assembly Biosciences by 30.4% during the fourth quarter. Millennium Management LLC now owns 133,666 shares of the biopharmaceutical company’s stock valued at $6,048,000 after buying an additional 31,195 shares in the last quarter. TIAA CREF Investment Management LLC lifted its stake in Assembly Biosciences by 46.8% during the fourth quarter. TIAA CREF Investment Management LLC now owns 72,331 shares of the biopharmaceutical company’s stock valued at $3,273,000 after buying an additional 23,064 shares in the last quarter. Finally, Teachers Advisors LLC lifted its stake in Assembly Biosciences by 16.1% during the fourth quarter. Teachers Advisors LLC now owns 28,964 shares of the biopharmaceutical company’s stock valued at $1,311,000 after buying an additional 4,025 shares in the last quarter. 77.26% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/15/assembly-biosciences-asmb-downgraded-by-zacks-investment-research.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.